Systematic characterization of antibody–drug conjugate targets in central nervous system tumors is a research paper published in Neuro-Oncology (2023). On theSindex it has a DataRank of 0.571. It has been cited 44 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.571
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Institutes of Health
Grant: U2C-CA233262
National Institutes of Health
Grant: R01-CA194005
National Institutes of Health
Grant: R01-CA188288
National Institutes of Health
Grant: P01-CA163205
National Institutes of Health
Grant: U54-CA210180
National Institutes of Health
Grant: P41-EB028741
National Institutes of Health
Grant: T32-CA009216
Ludwig Center at Harvard
Grant: P30-CA06516
NCI NIH HHS
Grant: P01 CA163205
NCI NIH HHS
Grant: P30 CA006516
NCI NIH HHS
Grant: U2C CA233262
NCI NIH HHS
Grant: R01 CA194005
NCI NIH HHS
Grant: T32 CA009216
NIBIB NIH HHS
Grant: P41 EB028741
NCI NIH HHS
Grant: U54 CA210180
National Brain Tumor Society
Pediatric Brain Tumor Foundation
Accelerate Brain Cancer Cure
MeSH Terms
Keywords
Additional file 1 of Unveiling the therapeutic potential of IHMT-337 in glioma treatment: targeting the EZH2-SLC12A5 axis
Additional file 1 of Unveiling the therapeutic potential of IHMT-337 in glioma treatment: targeting the EZH2-SLC12A5 axis
Additional file 2 of Unveiling the therapeutic potential of IHMT-337 in glioma treatment: targeting the EZH2-SLC12A5 axis
Additional file 2 of Unveiling the therapeutic potential of IHMT-337 in glioma treatment: targeting the EZH2-SLC12A5 axis
Additional file 3 of Unveiling the therapeutic potential of IHMT-337 in glioma treatment: targeting the EZH2-SLC12A5 axis
Additional file 3 of Unveiling the therapeutic potential of IHMT-337 in glioma treatment: targeting the EZH2-SLC12A5 axis
Additional file 4 of Unveiling the therapeutic potential of IHMT-337 in glioma treatment: targeting the EZH2-SLC12A5 axis
Additional file 4 of Unveiling the therapeutic potential of IHMT-337 in glioma treatment: targeting the EZH2-SLC12A5 axis
Additional file 5 of Unveiling the therapeutic potential of IHMT-337 in glioma treatment: targeting the EZH2-SLC12A5 axis
Additional file 5 of Unveiling the therapeutic potential of IHMT-337 in glioma treatment: targeting the EZH2-SLC12A5 axis
Additional file 6 of Unveiling the therapeutic potential of IHMT-337 in glioma treatment: targeting the EZH2-SLC12A5 axis
Additional file 6 of Unveiling the therapeutic potential of IHMT-337 in glioma treatment: targeting the EZH2-SLC12A5 axis